Working… Menu

Transcranial Direct Current Stimulation (tDCS) Cost-utility-analysis in Medical Care on Depressive Episode With One Drug Therapy Failure. (DISCO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03758105
Recruitment Status : Recruiting
First Posted : November 29, 2018
Last Update Posted : January 20, 2021
Information provided by (Responsible Party):
Nantes University Hospital

Brief Summary:

The purpose of this study is to determine the transcranial direct current stimulation (tDCS) cost-utility in the depression therapy.

This is a 3 years medico-economics study with 1 year follow-up period involving patients with 1 or 2 depression treatment(s) failed.

Eligible subject will be randomized in 2 groups, usual care with tDCS cure (arm A) or only usual care (arm B).

Condition or disease Intervention/treatment Phase
Depression Other: tDCS associated with usual care Other: Usual care Not Applicable

Detailed Description:

Transcranial direct current stimulation is a non-invasive brain neuromodulation technique. tDCS can be a new therapy in depression.

This study focuses on tDCS cost-utility-analysis. Each patient is following during 12 months. Patients are randomized in 2 arms. Arm A usual care with tDCS cure or arm B usual care without tDCS.

Patient in arm A get a initial tDCS cure one week after randomization. If these patients are answering to the treatment, they can have a new cure in case of relapse. This new cure can start from the second month following initial treatment.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 214 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Transcranial Direct Current Stimulation (tDCS) Cost-utility-analysis in Medical Care on Depressive Episode With One Drug Therapy Failure.
Actual Study Start Date : February 4, 2019
Estimated Primary Completion Date : July 2023
Estimated Study Completion Date : July 2023

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Usual care and tDCS (Arm A)
Arm A patient receives a first tDCS treatment in association with usual care (medication, psychotherapy...). If the patient is responding to tDCS, he can have other tDCS treatments in case of relapse.
Other: tDCS associated with usual care

A tDCS cure will be given to the group "tDCS", one week after their randomization.

This will be done in association with usual care: medication and psychotherapy Parameters: Anodal stimulation on dorso-lateral prefrontal cortex left, 2mA current.

Treatment will consist of 15 days with 30 minutes stimulation per day, 5 days a week for 3 weeks.

Active Comparator: Usual care without tDCS (Arm B)
Arm B patient receives usual care: medication management and psychotherapy.
Other: Usual care
Medication and psychotherapy as prescribed in usual care

Primary Outcome Measures :
  1. Cost-utility ratio, according to collective perspective of tDCS use in depression compared to usual care without active tDCS. [ Time Frame: 12 months ]

    The utility will be measured by :

    Quality Adjusted Life Year (QALYs) as estimated from responses to the Euroqol-5 Dimensions (EQ-5D) health-related quality of life questionnaire. The questionnaire focuses on 5 dimensions: mobility, personal autonomy, current activities, pain/discomfort and anxiety/depression. For each of these dimensions, 5 answers are possible.

    The costs will be measured by the addition of the following costs:

    Drugs dispensing via Health insurance database "National system of information of the French health insurance" (SNIIRAM), hospitalizations, work stoppages and care consumption collected in a declarative patient questionnaire.

Secondary Outcome Measures :
  1. Budget impact analysis of spreading the most efficient strategy for using tDCS [ Time Frame: 5 years ]
    Comparison of intervention costs on the study sample and projection of these costs over 5 years, from the health insurance and hospital perspectives

  2. Response rate [ Time Frame: at baseline, at the end of each tDCS cure (for Arm A patients) through study completion (12 months) and at 12 months for all patients ]
    Response is defined as follows: decrease of the MADRS score by at least 50% compared to baseline score. MADRS stands for Montgomery-Asberg Depression Rating Scale. It is used to measure the severity of depressive episodes in patients with mood disorders. The questionnaire includes questions on the following symptoms 1. Apparent sadness 2. Reported sadness 3. Inner tension 4. Reduced sleep 5. Reduced appetite 6. Concentration difficulties 7. Lassitude 8. Inability to feel 9. Pessimistic thoughts 10. Suicidal thoughts and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. A score from 0 to 6 being normal/symptom absent and a score >34 being severe depression.

  3. Remission rate [ Time Frame: 12 months ]
    Remission rate is defined as follows: MADRS score < 10 (see detailed description of MADRS in outcome 3)

  4. Relapse-free survival [ Time Frame: 12 months ]
    Number of patients with no relapse. Relapse is defined as follows: MADRS ≥ 20 (see detailed description of MADRS in outcome 3)

  5. MADRS score [ Time Frame: At Baseline, one month, 2 months, 6 months and 12 months. ]
    MADRS score (see detailed description of MADRS in outcome 3)

  6. Beck Depression Inventory (BDI) score [ Time Frame: At Baseline, one month, 2 months, 6 months and 12 months. ]
    The BDI is 13-item multiple-choice self-report inventory, for measuring the severity of depression. The global score is an addition of each item's score and ranges from 0 (minimal depression) to 39 (severe depression).

  7. Clinical Global Impression (CGI) score [ Time Frame: At Baseline, one month, 2 months, 6 months and 12 months. ]
    The Clinical Global Impression (CGI) rating scales are measures of symptom severity, treatment response and the efficacy of treatments in treatment studies of patients with mental disorders. Each scale is rated from 0 to 7. 0 being the best level and 7 the worst level.

  8. MOCA Score (Montreal Cognitive Assessment) [ Time Frame: At Baseline, one month, 2 months, 6 months and 12 months. ]
    Thirty items assessing multiple cognitive domains are contained in the MoCA: short-term memory (5 points); visuospatial abilities via clock drawing (3 points), and a cube copy task (1 point); executive functioning via an adaptation of Trail Making Test Part B (1 point), phonemic fluency (1 point), and verbal abstraction (2 points); attention, concentration, and working memory via target detection (1 point), serial subtraction (3 points), digits forward (1 point), and digits backward (1 point); language via confrontation naming with low-familiarity animals (3 points), and repetition of complex sentences (2 points); and orientation to time and place (6 points)

  9. Adverse events linked to the medical treatment for depression [ Time Frame: 12 months ]
    Number and types of adverse events linked to the medical treatment for depression

  10. Rate of suicide attempts [ Time Frame: 12 months ]
    number of suicide attempts per patient

  11. Rate of suicides [ Time Frame: 12 months ]
    number of suicides

  12. Treatment(s) switch(es) [ Time Frame: At Baseline, one month, 2 months, 6 months and 12 months. ]
    Number of treatment switches per patient

  13. Treatment(s) dose increase [ Time Frame: At Baseline, one month, 2 months, 6 months and 12 months. ]
    Number of drug(s) dose(s) increases prescribed to the patient

  14. Treatments combination(s) [ Time Frame: at Baseline, one month, 2 months, 6 months and 12 months. ]
    List of drugs (name) prescribed to the patient

  15. Declarative drug compliance via the MARS (Medication Adherence Report Scale) [ Time Frame: at baseline and at 12 months ]
    MARS is the Medication Adherence Report Scale, including 10 questions, the global score ranges from 0 to 10, 0 corresponds to the worst drug compliance and 10 to an excellent drug compliance

  16. Declarative drug compliance via the CRS (Clinician Rating Scale) [ Time Frame: at baseline and at 12 months ]
    CRS is the Clinician Rating Scale , including 7 questions, the global score ranges from 1 to 7, 7 being the worst level of drug compliance.

  17. Total number of tDCS sessions [ Time Frame: 12 months ]
    total number of tDCS sessions per patient

  18. Number of days between the successive tDCS cures [ Time Frame: 12 months ]
    Number of days between end of tDCS cure X and beginning of cure X+1, for each patient

  19. Adverse events linked to tDCS [ Time Frame: 12 months ]
    Number and types of adverse events linked to the tDCS

  20. Compliance with tDCS [ Time Frame: 12 months ]
    number of missed sessions over the number of planned sessions, per patient

  21. Patient acceptability of the tDCS technique: Analog Visual Scale [ Time Frame: at the end of the first tDCS cure (up to one month) ]
    Analog Visual Scale of acceptability of the tDCS completed by the patient, ranging from 0 to 10. 0 being "not acceptable" and 10 being "totally acceptable"

  22. professional status [ Time Frame: At baseline ]
    patient's professional status (active, unemployed, retired...)

  23. Impact of the implementation of the tDCS on the organization of care [ Time Frame: 12 months ]
    The organizational impact of the tDCS will be evaluated from the point of view of doctors, nurse and patients: staff, equipment, maintenance, location and mobilization time of these resources, using a specific questionnaire

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Depression according to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) with 1 or 2 failed antidepressant treatments for the current episode.
  • MADRS score superior or equal to 15.
  • Patient agreeing to participate in the study
  • Patient able to answer questionnaires and able to go at research center for follow-up visit.
  • Patient with social insurance

Exclusion Criteria:

  • Electroconvulsive therapy or repetitive transcranial magnetic stimulation for current depressive episode.
  • Depressive episode with psychotic symptoms or mixed.
  • Schizophrenia or addiction to another substance than nicotine
  • Severe neurological disorder (like epilepsy, neurological affect, neurological disease)
  • Severe and / or progressive somatic pathology (leave to the investigator judgment) preventing from participation in the study.
  • tDCS specific contraindications (intracerebral metallic implant, pacemaker)
  • Pregnancy or breast feeding.
  • Woman of childbearing age without contraception (hormonal or with medical device).
  • Participation in another interventional clinical trial
  • legal protection
  • Persons incarcerated or in obligation of treatment / medical treatment order.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03758105

Layout table for location contacts
Contact: Anne Sauvaget, MD +
Contact: Cécile DERT +33 2 53 48 28 52

Layout table for location information
CHU d'Angers Recruiting
Angers, France
Contact: Bénédicte GOHIER, Phd    02 41 35 36 37   
Clinique Mirambeau Recruiting
Anglet, France, 64600
Contact: Christophe DAUDET    33559523300   
CHRU de Besançon Recruiting
Besançon, France
Contact: Emmanuel HAFFEN, Phd    03 81 66 81 66   
Chu Clermont Ferrand Recruiting
Clermont-Ferrand, France, 63003
Contact: Pierre Michel LLORCA    33473750750   
CHU de Dijon Recruiting
Dijon, France
Contact: Benoit TROJAK, Phd    03 80 29 30 31   
Chu de Lyon Recruiting
Lyon, France
Contact: Emmanuel POULET    33472110009   
Nantes University Hospital Recruiting
Nantes, France, 44100
Contact: Anne Sauvaget, MD    +33 2 40 08 47 95   
Contact: Annabelle Rivalland    +33 253 48 26 53   
Aphp Hopital Saint Antoine Recruiting
Paris, France
Contact: Stéphane MOUCHABAC    33149282645   
CH Henri Laborit (Poitiers) Recruiting
Poitiers, France
Contact: Nematollah JAAFARI, Phd    05 49 44 57 57   
Centre hospitalier Guillaume Regnier Rennes Recruiting
Rennes, France, 35000
Contact: dominique DRAPIER    +33299333900   
CH du Rouvray - Rouen Recruiting
Rouen, France
Contact: Maud ROTHARMEL, Md    02 32 95 12 34   
CHU de Tours / CHRU de Tours Recruiting
Tours, France
Contact: WISSAM EL HAGE, Phd    02 47 47 47 47   
Sponsors and Collaborators
Nantes University Hospital
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Nantes University Hospital Identifier: NCT03758105    
Other Study ID Numbers: RC17_0493
First Posted: November 29, 2018    Key Record Dates
Last Update Posted: January 20, 2021
Last Verified: January 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Nantes University Hospital:
health economics
Additional relevant MeSH terms:
Layout table for MeSH terms
Behavioral Symptoms